EUVIMEDEUVIMED entdecken
Crossref

TRIM37‐Mediated Ubiquitination and Degradation of KMT2D Activates JAK2‐STAT3 Signaling to Promote Diffuse Large B‐Cell Lymphoma Progression

Yongcheng Sun, Bing Xiu, Miao Zhou, Shujun Yang, Zhijuan Xu, Zanzan Wang, Ping Zhang, Lixia Sheng, Guifang Ouyang, Aibin Liang iD

Hematological Oncology · 2026

DOI: 10.1002/hon.70191 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematological Oncology, 2026. Verfasst von Yongcheng Sun und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, STAT3 Transcription Factor, Janus Kinase 2, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse large B‐cell lymphoma (DLBCL) is the most common and clinically aggressive subtype of non‐Hodgkin lymphoma, yet key molecular drivers remain incompletely defined. Here, we identify the tripartite motif E3 ligase TRIM37 as a disease‐relevant oncogenic factor in DLBCL. TRIM37 was markedly upregulated in patient specimens and cell lines, and high expression correlated with poor prognosis. Loss‐of‐function studies showed that TRIM37 silencing suppressed proliferation and clonogenicity, triggered apoptosis, and restrained tumor growth in vivo. Mechanistically, TRIM37 promoted ubiquitin‐proteasome degradation of the enhancer‐associated histone methyltransferase KMT2D, reducing H3K4me1 deposition at the SOCS3 regulatory region, repressing SOCS3, and thereby sustaining JAK2‐STAT3 phosphorylation. Rescue experiments supported causality: co‐silencing KMT2D or enforcing TRIM37 expression reversed these effects, while JAK2 inhibitor treatment reproduced the impact of TRIM37 loss. Collectively, these findings show that TRIM37 drives DLBCL progression by destabilizing KMT2D to disable SOCS3‐mediated negative feedback on JAK2‐STAT3 and highlight TRIM37 as a potential therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseSTAT3 Transcription FactorJanus Kinase 2Ubiquitin-Protein LigasesNeoplasm ProteinsTripartite Motif ProteinsNuclear ProteinsDNA-Binding ProteinsHumansAnimalsUbiquitinationMiceSignal TransductionDisease ProgressionCell Line, TumorFemale

Stichwörter der Autor:innen

DLBCLJAK2‐STAT3KMT2DTRIM37ubiquitination

Substanzen

STAT3 Transcription FactorJanus Kinase 2STAT3 protein, humanUbiquitin-Protein LigasesJAK2 protein, humanNeoplasm ProteinsTripartite Motif ProteinsTRIM37 protein, humanKMT2D protein, humanNuclear Proteins

Autor:innen und Institutionen

  • Department of Haematology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Department of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo, China.
  • Department of Scientific Research, Ningbo Medical Center Lihuili Hospital, Ningbo, China.

ORCID-Profile: Aibin Liang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Sun, Y., Xiu, B., Zhou, M., Yang, S., Xu, Z., Wang, Z., Zhang, P., Sheng, L., Ouyang, G., & Liang, A. (2026). TRIM37‐Mediated Ubiquitination and Degradation of KMT2D Activates JAK2‐STAT3 Signaling to Promote Diffuse Large B‐Cell Lymphoma Progression. Hematological Oncology. https://doi.org/10.1002/hon.70191

Vancouver

Sun Y, Xiu B, Zhou M, Yang S, Xu Z, Wang Z, et al. TRIM37‐Mediated Ubiquitination and Degradation of KMT2D Activates JAK2‐STAT3 Signaling to Promote Diffuse Large B‐Cell Lymphoma Progression. Hematological Oncology. 2026. doi:10.1002/hon.70191

BibTeX
@article{Sun2026,
  author = {Sun, Yongcheng and Xiu, Bing and Zhou, Miao and Yang, Shujun and Xu, Zhijuan and Wang, Zanzan and Zhang, Ping and Sheng, Lixia and Ouyang, Guifang and Liang, Aibin},
  title = {TRIM37‐Mediated Ubiquitination and Degradation of KMT2D Activates JAK2‐STAT3 Signaling to Promote Diffuse Large B‐Cell Lymphoma Progression},
  journal = {Hematological Oncology},
  year = {2026},
  doi = {10.1002/hon.70191}
}
Kostenlos starten →